NewsNation covers recent studies that it says show GLP-1 weight loss drugs may slow biological aging. Tap through for which studies and what they measured.
Recap by typeshit. Full story at NewsNation.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
The company says the new application covers engineered cells that release GLP-1, GIP, GLP-2 and other peptides. It's investigational and not FDA approved.
In an eight-week monkey study, lean mass was 6% of weight lost with the antibody plus semaglutide versus 22% on semaglutide alone. iBio plans human trials in early 2027.
Loading…